Tedizolid for the management of human infections: in vitro characteristics

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Jeffrey B LockeKenneth Bartizal

Abstract

The emerging antibiotic resistance of Gram-positive pathogens represents a significant challenge to the management of human infections. The novel oxazolidinone tedizolid demonstrates antimicrobial activity across a broad range of Gram-positive pathogens and greater potency than linezolid against wild-type and drug-resistant pathogens, including linezolid-resistant Staphylococcus aureus strains possessing mutations in chromosomal genes encoding 23S rRNA or ribosomal proteins L3 or L4. Strains harboring such mutations are also selected for much less frequently with tedizolid than with linezolid. In addition, tedizolid has a significant potency advantage over linezolid-resistant strains carrying the horizontally transferable cfr gene. Methylation of A2503 of 23S rRNA by the Cfr methyltransferase confers resistance to linezolid (and a variety of other 50S ribosomal subunit-targeted antibiotics) but not to tedizolid because of structural differences in A-ring C5 substituents between the 2 drugs. The greater potency and improved resistance profile of tedizolid provides the microbiologic basis for considering this molecule as an alternative to linezolid for the treatment of serious infections caused by Gram-positive pathogens.

References

Aug 22, 2000·Antimicrobial Agents and Chemotherapy·S SchwarzC Kehrenberg
Jan 24, 2009·The Journal of Antimicrobial Chemotherapy·David M LivermoreNeil Woodford
Feb 17, 2009·The Journal of Antimicrobial Chemotherapy·Ronald N JonesMariana Castanheira
Aug 28, 2009·The Journal of Antimicrobial Chemotherapy·Lucio Vera-CabreraJorge Castro-Garza
Oct 7, 2009·Antimicrobial Agents and Chemotherapy·Jeffrey B LockeKaren Joy Shaw
Feb 24, 2010·Antimicrobial Agents and Chemotherapy·Carmen BetriuJuan J Picazo
Feb 5, 2011·European Journal of Medicinal Chemistry·Weon Bin ImSung-Hwa Yoon
Feb 9, 2011·International Journal of Antimicrobial Agents·Ian M GouldJavier Garau
Jun 8, 2011·Antimicrobial Agents and Chemotherapy·Jacqueline M LaMarreAlexander S Mankin
Oct 20, 2011·The Journal of Antimicrobial Chemotherapy·Robert C Moellering
Oct 26, 2011·Antimicrobial Agents and Chemotherapy·Jeffrey B LockeKaren Joy Shaw
Dec 7, 2011·Antimicrobial Agents and Chemotherapy·Katherine S Long, Birte Vester
Dec 24, 2011·Annals of the New York Academy of Sciences·Karen Joy Shaw, Michael R Barbachyn
Feb 14, 2012·Expert Opinion on Investigational Drugs·Zeina A Kanafani, G Ralph Corey
May 15, 2012·International Journal of Medical Microbiology : IJMM·Immaculada Quiles-MeleroJesús Mingorance
Jul 4, 2012·Current Opinion in Pharmacology·Karen Bush
Sep 6, 2012·The Journal of Antimicrobial Chemotherapy·Bing GuRomney M Humphries
Feb 14, 2013·JAMA : the Journal of the American Medical Association·Philippe ProkocimerAnita Das

❮ Previous
Next ❯

Citations

Jul 18, 2014·Expert Review of Respiratory Medicine·Christian Woods, Gene Colice
Nov 27, 2015·Expert Opinion on Pharmacotherapy·Shang-Yi LinPo-Ren Hsueh
Feb 11, 2016·Advances in Therapy·Philippe MontraversElise Guivarch
Jan 17, 2016·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Hua-chen YuYi-mu Lin
Aug 2, 2015·Current Opinion in Pharmacology·Laura MorataAlex Soriano
Sep 1, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J CaiJ Shen
Mar 22, 2016·Expert Opinion on Therapeutic Patents·Oludotun A Phillips, Leyla H Sharaf
Jun 25, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Steven D Burdette, Robin Trotman
Sep 1, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jose M MunitaCesar A Arias
Feb 25, 2015·Infectious Diseases and Therapy·Jeffrey M Rybak, Karrine Roberts
Oct 17, 2016·Enfermedades infecciosas y microbiología clínica·Santiago Pérez-ParraFederico García-García
Feb 1, 2017·Expert Opinion on Drug Metabolism & Toxicology·Darrell McBrideMichael J Durkin
Jan 15, 2017·Biochemical Pharmacology·Sheo B SinghLynn L Silver
Sep 20, 2016·MedChemComm·Jesse A JonesKirk E Hevener
Feb 27, 2018·Expert Opinion on Pharmacotherapy·A KhanI M Gould
Apr 5, 2018·Expert Review of Anti-infective Therapy·Ayesha KhanCesar A Arias
Sep 20, 2017·Antimicrobial Agents and Chemotherapy·Barbara A Brown-Elliott, Richard J Wallace
Mar 24, 2017·Journal of Clinical Microbiology·Barbara A Brown-Elliott, Richard J Wallace
Nov 26, 2014·Antimicrobial Agents and Chemotherapy·Andrew F ShorrPhilippe Prokocimer
Jan 22, 2019·Current Opinion in Infectious Diseases·Elda RighiMatteo Bassetti
May 31, 2014·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Voon OngPhilippe Prokocimer
Dec 1, 2017·Expert Review of Clinical Pharmacology·Kenna D PayneRonald G Hall
Feb 26, 2016·The Pediatric Infectious Disease Journal·John S BradleyPhilippe Prokocimer
May 26, 2020·Expert Review of Clinical Pharmacology·Alberto A Carena, Martin E Stryjewski
Sep 12, 2014·Current Opinion in Infectious Diseases·Natasha E Holmes, Benjamin P Howden
Apr 19, 2017·FEMS Microbiology Reviews·Timothy J Foster
Dec 22, 2016·The Journal of Antimicrobial Chemotherapy·Abed Zahedi BialvaeiHossein Samadi Kafil
Apr 8, 2020·Antimicrobial Agents and Chemotherapy·Lara M AlmeidaMichael S Gilmore
Nov 23, 2016·Current Infectious Disease Reports·Kyle C Molina, Vanthida Huang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.